Aeson Therapeutics


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Dehydroepiandrosterone (DHEA) may have therapeutic uses against cardiovascular disease, immune disorders, cancer and other diseases, but the hormone is a precursor of androgens and estrogens and can cause undesirable side effects. RCT formed Aeson Therapeutics to develop fluasterone, a synthetic steroid that may be more effective than DHEA without the adverse side effects. Fluasterone development targets include treatment of lipid disorders, inflammatory diseases and as a cancer chemoprevention ...Show all

Dehydroepiandrosterone (DHEA) may have therapeutic uses against cardiovascular disease, immune disorders, cancer and other diseases, but the hormone is a precursor of androgens and estrogens and can cause undesirable side effects. RCT formed Aeson Th...Show all

Company (Acquired)

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Aeson Therapeutics $0M May 24, 2006
Tragara Pharmaceuticals $70.3M Apr 24, 2019
Kanisa Pharmaceuticals $25M Dec 13, 2004
See all 49 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Aeson Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 49 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)